Jiheng Pharmaceutical has released its 2026 half-year performance forecast, expecting a net loss attributable to shareholders of 18 million to 23 million yuan for the first half, a year-on-year decline of 86.26% to 82.44%. The company stated that after completing bankruptcy restructuring at the end of 2025, it has divested its building materials segment and overseas business, eliminating related impacts. However, during the current period, external market changes led to significant fluctuations in chemical raw materials, and downstream industry demand remained weak. Multiple factors weighed on profits.
Chongqing Sansheng Building Materials Co LtdJiheng Pharmaceutical's divestiture of building materials segment and weak downstream demand indicate reduced demand for building materials.